2025-11-03T12:39:24+00:00 2025-06-30 440160260 Forvis Mazars LLP 135 West 50th Street New York NY 10020 990 2024-07-01 330841281 PANCREATIC CANCER ACTION NETWORK INC PANC 3107250025 2101 Rosencrans Avenue 3200 El Segundo CA 90245 Julie Fleshman President & CEO 3107250025 2025-11-03 true Aaron Shapiro P01333816 2128127000 2025-11-15 2024 2025-03-06 01:10:19Z JULIE FLESHMAN 2101 Rosencrans Avenue 3200 El Segundo CA 90245 63133398 false X WWW.PANCAN.ORG X 1999 CA TO ADVANCE RESEARCH, SUPPORT PATIENTS, AND CREATE HOPE FOR PEOPLE WHO HAVE PANCREATIC CANCER. 18 17 183 2645 0 39686375 40266661 8510939 3533886 2184295 1426840 -3300071 -3002240 47081538 42225147 125000 217500 0 0 27626013 23982931 1167832 1015710 6128718 31624085 22380960 60542930 47597101 -13461392 -5371954 56273833 41025560 21060860 10502244 35212973 30523316 X OUR MISSION IS TO TAKE BOLD ACTION TO IMPROVE THE LIVES OF EVERYONE IMPACTED BY PANCREATIC CANCER BY ADVANCING SCIENTIFIC RESEARCH, BUILDING COMMUNITY, SHARING KNOWLEDGE, AND ADVOCATING FOR PATIENTS. false false 13822863 217500 3533886 RESEARCH & SCIENTIFIC AFFAIRS - PANCAN FUNDS GROUNDBREAKING RESEARCH INITIATIVES THAT WILL TRANSFORM THE WAY PANCREATIC CANCER IS DETECTED AND TREATED. WE FUND RESEARCH GRANTS TO INDIVIDUAL INVESTIGATORS AND LARGE-SCALE, MULTI-INSTITUTIONAL CLINICAL PROJECTS THAT ARE FOCUSED ON ADVANCING NEW TREATMENTS AND EARLY DETECTION FOR PANCREATIC CANCER. WE INVESTED $13.6 MILLION IN RESEARCH & SCIENTIFIC AFFAIRS IN FISCAL YEAR 2025. OUR RESEARCH FUNDING SUPPORTED IMPORTANT RESEARCH PROJECTS AT INSTITUTIONS ACROSS THE COUNTRY, AND PANCAN'S PRECISION PROMISESM ADAPTIVE CLINICAL TRIAL, EARLY DETECTION INITIATIVE, KNOW YOUR TUMOR PRECISION MEDICINE SERVICE, AND SPARK HEALTH DATA INTEGRATION PLATFORM. SINCE 2003, PANCAN HAS AWARDED 237 RESEARCH GRANTS TO 217 SCIENTISTS AT 78 INSTITUTIONS. PANCAN'S CUMULATIVE RESEARCH INVESTMENT IS NOW MORE THAN $249 MILLION, MAKING A SIGNIFICANT IMPACT ON THE DIAGNOSIS, TREATMENT AND CARE OF TODAY'S PATIENTS AND THOSE WHO WILL BE DIAGNOSED IN THE FUTURE. 6917114 COMMUNITY ENGAGEMENT - NEARLY 55 VOLUNTEER AFFILIATES WITH MORE THAN 2,645 VOLUNTEERS LEADERS RAISE AWARENESS OF PANCAN AND THE DISEASE AND EDUCATE THEIR COMMUNITIES ABOUT PANCREATIC CANCER. VOLUNTEERS HOSTED NEARLY 55 PURPLESTRIDE EVENTS ACROSS THE COUNTRY THIS YEAR, WITH 62,831 PARTICIPANTS SUPPORTING SURVIVORS, FAMILIES AND FRIENDS, AS WELL AS PROVIDING EDUCATIONAL INFORMATION AT THE EVENTS. PURPLESTRIDE PARTICIPANTS RAISED MORE THAN $17 MILLION IN FISCAL YEAR 2025. WE ARE ALSO A FOUNDING MEMBER OF THE WORLD PANCREATIC CANCER COALITION, COMPOSED OF MORE THAN 100 PANCREATIC CANCER PATIENT ADVOCACY GROUPS FROM MORE THAN 30 COUNTRIES AND SIX CONTINENTS. THE COALITION HAS AN ONGOING COMMITMENT TO CONTINUING EDUCATION FOR ITS MEMBERS AND HOSTS WORLD PANCREATIC CANCER DAY EVERY NOVEMBER TO RAISE GLOBAL AWARENESS OF THE DISEASE. 4670773 PATIENT SERVICES - PROVIDES FREE, PERSONALIZED INFORMATION AND RESOURCES ABOUT PANCREATIC CANCER, TREATMENT OPTIONS, CLINICAL TRIALS, DIET AND NUTRITION, SPECIALISTS AND SUPPORT RESOURCES TO HELP PATIENTS, CAREGIVERS AND HEALTHCARE PROVIDERS. WE HAVE THE LARGEST, MOST UP-TO-DATE CLINICAL TRIALS DATABASE IN THE COUNTRY AND PROVIDE CONSTITUTENTS WITH PERSONALIZED SEARCHES SO THAT THEY UNDERSTAND ALL OF THEIR TREATMENT OPTIONS. OUR EXPERT PATIENT SERVICES CASE MANAGERS SHARE MORE RESOURCES AND SPEAK WITH MORE PANCREATIC CANCER PATIENTS THAN ANY OTHER ORGANIZATION IN THE WORLD. LAST YEAR ALONE, WE HAD MORE THAN 38,000 INTERACTIONS WITH PATIENTS WITH PANCREATIC CANCER, THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFFESSIONALS. 971774 GOVERNMENT AFFAIRS AND ADVOCACY - WE DRIVE LEGISLATIVE SUPPORT FOR INCREASED FEDERAL RESEARCH FUNDING FOR PANCREATIC CANCER. OUR GRASSROOTS ADVOCACY EFFORTS LED TO THE PASSAGE OF THE RECALCITRANT CANCER RESEARCH ACT, INCREASED RESEARCH DOLLARS FOR PANCREATIC CANCER AT THE NATIONAL CANCER INSTITUTE, AND LED TO A NEW PANCREATIC CANCER RESEARCH PROGRAM AT THE DEPARTMENT OF DEFENSE. SINCE OUR FOUNDING, FEDERAL RESEARCH FUNDING FOR PANCREATIC CANCER HAS INCREASED BY 1075 PERCENT AND CONTINUES TO INCREASE EACH YEAR DUE TO OUR EFFORTS. 971774 26382524 true true false true false false false false false false true false false true true true true false false false false false false true true false false true false true false false false false false false false false false false true false false false false false false false false false true 89 0 183 true false false false false false false false false false false false false X 18 17 false false false false false false false true true false true true true true true true true true true true false false CA CO CT DE DC FL GA AL HI ID IL IN IA KS KY LA ME AK MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA AZ RI SC SD TN TX UT VT VA AR WA WV WI WY X X SUZANNE NEUMAN 3107250025 2101 Rosencrans Avenue Suite 3200 El Segundo CA 90245 JULIE FLESHMAN PRESIDENT & CEO/DIRECTOR 50.0 X X 586305 0 78045 KAREN YOUNG CHAIR 2.0 X X 0 0 0 LINDA AMUSO VICE CHAIR 2.0 X X 0 0 0 BARBARA KENNER PHD BOARD MEMBER 2.0 X 0 0 0 CRAIG ROGERSON BOARD MEMBER 2.0 X 0 0 0 DENNIS CRONIN BOARD MEMBER 2.0 X 0 0 0 ERIC PARK BOARD MEMBER 2.0 X 0 0 0 JAY BACKSTROM MD BOARD MEMBER 2.0 X 0 0 0 KARYN TEMPLE BOARD MEMBER 2.0 X 0 0 0 LISA KULOK BOARD MEMBER 2.0 X 0 0 0 MACE ROTHENBERG MD BOARD MEMBER 2.0 X 0 0 0 NANCY STAGLIANO PHD BOARD MEMBER 2.0 X 0 0 0 NICOLE RUBIN BOARD MEMBER 2.0 X 0 0 0 PETER CASHION BOARD MEMBER 2.0 X 0 0 0 PRESTON BRICE BOARD MEMBER 2.0 X 0 0 0 RICH HUME BOARD MEMBER 2.0 X 0 0 0 ROD WILLIAMS MBA BOARD MEMBER 2.0 X 0 0 0 SHARON BITTMAN BOARD MEMBER 2.0 X 0 0 0 ANAT KENDAL CHIEF FINANCIAL & Business Operations Officer 50.0 X 353066 0 58316 ANNA BERKENBILT CHIEF SCIENTIFIC & MEDICAL OFFICER 50.0 X 347687 0 53805 EDWINA MOSSETT CHIEF PEOPLE OFFICER 50.0 X 328642 0 45993 JILL DAVIS CHIEF GROWTH OFFICER 50.0 X 350000 0 37656 LYNN MATRISIAN CHIEF SCIENCE ADVISOR 50.0 X 339237 0 31015 SUDHEER DOSS CHIEF BUSINESS OFFICER 50.0 X 370304 0 52020 JODI LIPE CHIEF MARKETING AND COMMUNICATION (through 6/24) 50.0 X 353814 0 25782 KENNETH STRODE SENIOR DIRECTOR (through 10/24) 50.0 X 262221 0 52743 LISA GRAY SENIOR VICE PRESIDENT, DEVELOPMENT ( through 6/24) 50.0 X 288712 0 20021 SARAH DOW VP NATIONAL LEADERSHIP GIVING 50.0 X 260552 0 46738 TAMMY BUIST SENIOR VP BUSINESS DEVELOPMENT 50.0 X 247988 0 45098 4088528 0 547232 84 true true false MEDIA STORM LLC PO BOX 6411 BRATTLEBORO VT 053026411 ADVERTISING 984435 RSM US LLP 5155 Paysphere Circle Chicago IL 60674 ACCOUNTING SERVICES 370594 BERRY CONSULTANTS LLC 3345 BEE CAVES RD SUITE 201 AUSTIN TX 78746 CONSULTING SERVICES 215000 VACO LLC PO Box 667 Brentwood TN 37024 CONTRACT STAFFING 187984 JOSEPH K KAMINSKI 2101 Rosecrans Ave Suite 3200 El Segundo CA 90245 CONSULTING SERVICES 160000 5 17506411 22760250 739525 40266661 CLINICAL RESEARCH CONTRACTS 541700 3533886 3533886 0 0 0 0 3533886 668643 668643 0 0 18239542 17481345 758197 0 758197 758197 17506411 3404913 -3404913 -3404913 -409 21993 -22402 -22402 Gain on Modification of Lease 900099 388395 388395 MISC REVENUE 900099 36680 36680 0 0 0 0 425075 42225147 3922281 0 -1963795 X 217500 217500 3080795 1702059 914007 464729 15683713 8664841 4653027 2365845 825219 455912 244825 124482 2061201 1165337 576760 319104 2332003 1318440 652535 361028 323814 323814 119141 119141 318317 318317 1015710 1015710 155118 155118 11657128 9178976 2147034 331118 1619007 1127894 122174 368939 332010 198843 74125 59042 2163963 486805 1415416 261742 666126 389293 177696 99137 341681 239181 74017 28483 486921 340850 105480 40591 217580 140272 48408 28900 462898 268665 194233 FINANCE & PROCESSING CHARGES 3085304 3085304 DONOR AND AFFILIATE ENGAGEMENT 431952 169339 2745 259868 0 0 0 0 47597101 26382524 15085859 6128718 7462455 3545482 318568 151529 14002396 11949001 221168 435868 0 0 0 0 21439 0 2451294 1370809 4906010 4311622 649515 594388 30128192 18239542 0 0 1018806 4738941 56273833 41025560 11002996 3939935 7586327 2224854 1144084 30540 0 0 1327453 4306915 21060860 10502244 16281408 14688681 18931565 15834635 35212973 30523316 56273833 41025560 -5371954 682297 0 X false true true false X 36292699 45222545 65007979 39686375 40266661 226476259 0 0 36292699 45222545 65007979 39686375 40266661 226476259 20812856 205663404 697700 1176978 1368795 1040995 668643 4953111 0 0 0 0 2780 425075 427855 231857225 45345255 0.88703 0.88400 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - OTHER, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - 2780.0, COLUMN E - 425075.0, COLUMN F - 427855.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 63324 0 254993 0 318317 0 47278784 0 47597101 0 1000000 0 250000 0 0 0 0 0 1000000 1000000 1000000 1000000 4000000 6000000 314265 252214 211478 318317 1096274 250000 250000 250000 250000 1000000 1500000 120132 105426 69496 63324 358378 Schedule C, Part II-A PANCAN ENGAGES IN DEVELOPING REPORT LANGUAGE FOR APPROPRIATIONS BILLS; DEVELOPING ALERTS TO OUR CONSTITUENTS REGARDING SPECIFIC LEGISLATION; PREPARING FOR AND ATTENDING VISITS ON CAPITAL HILL BY OUR CONSTITUENTS AND THE PUBLIC BOTH IN PERSON AND VIRTUALLY; GIVING UNINVITED AND INVITED TESTIMONY OR WRITTEN RESPONSES DURING LEGISLATIVE HEARINGS; AND DEVELOPING GENERAL EDUCATIONAL MESSAGES THROUGH MEDIA CAMPAIGNS THAT DO OR DO NOT INCLUDE A CALL FOR ACTION. 297674 35233 262441 1229638 905632 324006 3378698 3370757 7941 594388 Right of use Asset 4121270 Deposits 76043 Trademarks 34057 457 Plan Assets 464503 Investments - Accrued Interest - C. Schwab 43068 4738941 Federal Income Taxes Finance Lease Obligations 4306915 4306915 43326817 682297 574491 0 1256788 42070029 155118 0 155118 42225147 48016474 574491 0 574491 47441983 155118 0 155118 47597101 X X X X true RKD Group 2701 N Dallas Parkway Ste 650 Plano TX 75093 General fundraising false 0 1015710 -1015710 0 1015710 -1015710 CA CO CT DE DC FL GA AL HI ID IL IN IA KS KY LA ME AK MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA AZ RI SC SD TN TX UT VT VA AR WA WV WI WY PURPLE STRIDE 17506411 17506411 0 315546 12423 37000 3039945 0 0 17506411 17506411 0 315546 12423 37000 3039945 3404914 -3404914 true Fred Hutchinson Cancer Center 1100 Fairview Ave N Seattle WA 98109 237156071 501(c)(3) 217500 FUND RESEARCH 1 0 Schedule I, Part II NAME AND ADDRESS OF ORGANIZATION OR GOVERNMENT FRED HUTCHINSON CANCER CENTER, 1100 FAIRVIEW AVE N, SEATTLE, WA 98109 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds THE PANCREATIC CANCER ACTION NETWORK ADMINISTERS ITS RESEARCH GRANTS PROGRAM IN HOUSE. THE AMOUNT OF THE GRANTS AND ELIGIBILITY CRITERIA ARE DETERMINED BY THE ORGANIZATION'S SCIENTIFIC LEADERSHIP IN ADVANCE OF PUBLIC NOTIFICATION OF GRANT AVAILABILITY. GRANTS ARE SELECTED BY SCIENTIFIC REVIEW PERFORMED BY A PANEL OF PEER EXPERTS. ALL GRANT AMOUNTS, ELIGIBILITY CRITERIA, AND REVIEW PROCESSES ARE DOCUMENTED ANNUALLY IN THE INDIVIDUAL GRANT APPLICATION PROCEDURE DOCUMENTS. GRANT AMOUNTS, GRANT RESTRICTIONS (INCLUDING USE OF FUNDS) AND REPORTING PROCESSES ARE SPECIFIED IN THE GRANT AGREEMENT BETWEEN THE GRANTEE'S INSTITUTION AND THE ORGANIZATION. PROGRESS REPORTS ARE REQUIRED FOR ALL GRANTS AWARDED. THESE PROGRESS REPORTS ARE COLLECTED AND REVIEWED BY THE GRANTS ASSOCIATE DIRECTOR AND DOCUMENTED IN THE INDIVIDUAL GRANT POST AWARD FILES. PROGRESS REPORTS INCLUDE A DESCRIPTION OF THE RESEARCH WORK ACCOMPLISHED, FUNDS USED, LESSONS LEARNED AND OTHER OUTCOMES. FINAL REPORTS ARE DUE WITHIN TWO MONTHS OF THE COMPLETION OF THE GRANT PERIOD AND MUST ACCOUNT FOR THE ENTIRE GRANT AMOUNT. PROGRAM STAFF COMMUNICATE DIRECTLY WITH GRANT RECIPIENTS TO RESOLVE QUESTIONS OR DISCREPANCIES. THIS PROCESS IS DOCUMENTED IN THE GRANT AGREEMENT BETWEEN THE GRANTEE INSTITUTION AND THE ORGANIZATION. THE PANCREATIC CANCER ACTION NETWORK HAS ESTABLISHED OTHER GRANT AGREEMENTS TO FUND SCIENTIFIC INITIATIVES IN CLINICAL TRIALS RESEARCH AND EARLY DETECTION OF PANCREATIC CANCER. X X X X X X true true false true false false false false false JULIE FLESHMAN PRESIDENT & CEO/DIRECTOR 563305 0 0 0 23000 0 36800 0 41245 0 664350 0 0 0 ANAT KENDAL CHIEF FINANCIAL & Business Operations Officer 343066 0 10000 0 0 0 13729 0 44587 0 411382 0 0 0 SUDHEER DOSS CHIEF BUSINESS OFFICER 370304 0 0 0 0 0 13800 0 38220 0 422324 0 0 0 JILL DAVIS CHIEF GROWTH OFFICER 350000 0 0 0 0 0 13800 0 23856 0 387656 0 0 0 ANNA BERKENBILT CHIEF SCIENTIFIC & MEDICAL OFFICER 347687 0 0 0 0 0 11617 0 42188 0 401492 0 0 0 LYNN MATRISIAN CHIEF SCIENCE ADVISOR 339237 0 0 0 0 0 9671 0 21344 0 370252 0 0 0 EDWINA MOSSETT CHIEF PEOPLE OFFICER 318642 0 10000 0 0 0 13274 0 32719 0 374635 0 0 0 JODI LIPE CHIEF MARKETING AND COMMUNICATION (through 6/24) 160814 0 0 0 193000 0 6713 0 19069 0 379596 0 0 0 LISA GRAY SENIOR VICE PRESIDENT, DEVELOPMENT ( through 6/24) 168712 0 0 0 120000 0 5255 0 14766 0 308733 0 0 0 KENNETH STRODE SENIOR DIRECTOR (through 10/24) 189185 0 10000 0 63036 0 8723 0 44020 0 314964 0 0 0 SARAH DOW VP NATIONAL LEADERSHIP GIVING 260552 0 0 0 0 0 10846 0 35892 0 307290 0 0 0 TAMMY BUIST SENIOR VP BUSINESS DEVELOPMENT 247988 0 0 0 0 0 10260 0 34838 0 293086 0 0 0 Schedule J, Part I, Line 4a Severance or change-of-control payment Jodi Lipe; $193,000; termed 06/28/24 Lisa Gray; $120,000; termed 06/30/24 Ken Strode; $63,036; termed 10/04/24 Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE FOLLOWING INDIVIDUAL PARTICIPATES IN A NON-QUALIFIED TAXABLE RETIREMENT PLAN OF THE ORGANIZATION. THE AMOUNT SHOWN REPRESENTS THE ORGANIZATION'S EMPLOYER CONTRIBUTION TO THE PLAN FOR THE YEAR ENDED JUNE 30, 2025: JULIE FLESHMAN $23,500 Schedule J, Part I, Line 5a Compensation contingent on revenues of the organization THE PERFORMANCE INCENTIVE PLAN REWARDS OUR VALUED TEAM MEMBERS IF CERTAIN REVENUE GOALS ARE REACHED. 34 732900 Market value 9 4875 Cost X SUPPLIES 1 500 Cost X GIFT CARDS 2 1250 Cost 0 false true false Schedule M, Part I Explanations of reporting method for number of contributions Securities - Publicly traded - The organization is reporting the number of contributions Food inventory - The organization is reporting the number of contributions Other - SUPPLIES - The organization is reporting the number of contributions Other - GIFT CARDS - The organization is reporting the number of contributions Form 990, Part III, Line 4a-4c Description of program services (Expenses $ 971,774 including grants of $) GOVERNMENT AFFAIRS AND ADVOCACY - WE DRIVE LEGISLATIVE SUPPORT FOR INCREASED FEDERAL RESEARCH FUNDING FOR PANCREATIC CANCER. OUR GRASSROOTS ADVOCACY EFFORTS LED TO THE PASSAGE OF THE RECALCITRANT CANCER RESEARCH ACT, INCREASED RESEARCH DOLLARS FOR PANCREATIC CANCER AT THE NATIONAL CANCER INSTITUTE, AND LED TO A NEW PANCREATIC CANCER RESEARCH PROGRAM AT THE DEPARTMENT OF DEFENSE. SINCE OUR FOUNDING, FEDERAL RESEARCH FUNDING FOR PANCREATIC CANCER HAS INCREASED BY 1075 PERCENT AND CONTINUES TO INCREASE EACH YEAR DUE TO OUR EFFORTS. Form 990, Part VI, Line 11b Review of form 990 by governing body THE ORGANIZATION'S AUDIT AND INVESTMENT COMMITTEE (AIC) RECEIVES AND REVIEWS THE DRAFT OF THE FORM 990, INCLUDING SCHEDULES, PRIOR TO THE FILING OF THE RETURN. A MEETING OF THE AIC, INCLUDING THE PRESIDENT AND CEO, VP OF FINANCE, THE CFO, THE CONTROLLER, AND THE OUTSIDE CPA FIRM, IS THEN HELD TO REVIEW AND REVISE THE DRAFT OF THE FORM 990 AS NECESSARY. UPON APPROVAL OF THE DRAFT FORM 990 BY THE AIC, THE FINAL FORM 990, WITH CHANGES REFLECTED, IF ANY, IS E-MAILED TO THE ENTIRE BOARD OF DIRECTORS FOR REVIEW PRIOR TO FILING. UPON BOARD APPROVAL, THE FINAL FORM 990 IS FILED ELECTRONICALLY. Form 990, Part VI, Line 12c Conflict of interest policy THE BOARD OF DIRECTORS IS REQUIRED TO SUBMIT AN UPDATED CONFLICT OF INTEREST STATEMENT ANNUALLY. TO THE EXTENT THAT RELATIONSHIPS ARE IDENTIFIED VIA THESE STATEMENTS AND OTHER INFORMATION, THE INDIVIDUAL'S CONSTITUENT RECORD IS UPDATED TO INCLUDE THIS INFORMATION, FACILITATING PERIODIC QUERIES, AS NECESSARY. THE MEMBER WITH A CONFLICT MUST IDENTIFY THE CONFLICT AT ANY BOARD MEETING WHERE THE CONFLICT IS RELEVENT. THE MEMBER CANNOT BE PRESENT AT ANY PART OF THE MEETING WHERE THE RELEVENT TOPIC IS DISCUSSED OR VOTED ON. THE MEMBER CANNOT BE COUNTED FOR A QUORUM. Form 990, Part VI, Line 15a Process to establish compensation of top management official MERCER CONDUCTED THE COMPENSATION REVIEW FOR EXECUTIVES IN JUNE 2024 AND FOR CEO IN JUNE 2025. THE BOARD COMPENSATION COMMITTEE IS RESPONSIBLE FOR THE ANNUAL REVIEW AND APPROVAL OF THE COMPENSATION FOR TOP-LEVEL EXECUTIVE MANAGEMENT, OFFICERS, AND KEY EMPLOYEES. THE CHIEF PEOPLE OFFICER MONITORS INDUSTRY SALARY LEVELS AND INFORMS THE COMMITTEE OF ANY CHANGES. TO SUPPORT THIS PROCESS, THE HUMAN RESOURCES TEAM USES SUBSCRIPTION-BASED COMPENSATION PLATFORMS THAT PROVIDE SALARY SURVEY DATA, MARKET BENCHMARKING TOOLS, AND ANALYTICS, ALLOWING PANCAN TO COMPARE PAY PRACTICES AGAINST PEER ORGANIZATIONS AND ENSURE COMPENSATION DECISIONS REMAIN ALIGNED WITH INDUSTRY STANDARDS. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER-LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR-PROFIT AND NOT-FOR-PROFIT ORGANIZATIONS ARE EVALUATED IN ORDER TO ATTRACT THE MOST TALENTED PERSONNEL. INFORMATION IS GATHERED, ANALYZED AND REPORTED TO THE COMMITTEE PRIOR TO THEIR MEETINGS ON COMPENSATION WITH THE INTENT OF ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. THE BOARD ESTABLISHES THE CEO/PRESIDENT SALARY LEVEL DURING THE EXECUTIVE SESSION OF A CALLED BOARD MEETING. ONCE APPROVED, EXECUTIVE COMPENSATION PACKAGES ARE FORMALIZED IN WRITING AND, ONCE ACCEPTED BY THE EXECUTIVE, RETAINED IN THE PERSONNEL FILE(S). Form 990, Part VI, Line 15b Process to establish compensation of other employees MERCER CONDUCTED THE COMPENSATION REVIEW FOR EXECUTIVES IN JUNE 2024 AND FOR CEO IN JUNE 2025. THE BOARD COMPENSATION COMMITTEE IS RESPONSIBLE FOR THE ANNUAL REVIEW AND APPROVAL OF THE COMPENSATION FOR TOP-LEVEL EXECUTIVE MANAGEMENT, OFFICERS, AND KEY EMPLOYEES. THE CHIEF PEOPLE OFFICER MONITORS INDUSTRY SALARY LEVELS AND INFORMS THE COMMITTEE OF ANY CHANGES. TO SUPPORT THIS PROCESS, THE HUMAN RESOURCES TEAM USES SUBSCRIPTION-BASED COMPENSATION PLATFORMS THAT PROVIDE SALARY SURVEY DATA, MARKET BENCHMARKING TOOLS, AND ANALYTICS, ALLOWING PANCAN TO COMPARE PAY PRACTICES AGAINST PEER ORGANIZATIONS AND ENSURE COMPENSATION DECISIONS REMAIN ALIGNED WITH INDUSTRY STANDARDS. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER-LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR-PROFIT AND NOT-FOR-PROFIT ORGANIZATIONS ARE EVALUATED IN ORDER TO ATTRACT THE MOST TALENTED PERSONNEL. INFORMATION IS GATHERED, ANALYZED AND REPORTED TO THE COMMITTEE PRIOR TO THEIR MEETINGS ON COMPENSATION WITH THE INTENT OF ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. THE BOARD ESTABLISHES THE CEO/PRESIDENT SALARY LEVEL DURING THE EXECUTIVE SESSION OF A CALLED BOARD MEETING. ONCE APPROVED, EXECUTIVE COMPENSATION PACKAGES ARE FORMALIZED IN WRITING AND, ONCE ACCEPTED BY THE EXECUTIVE, RETAINED IN THE PERSONNEL FILE(S). Form 990, Part VI, Line 19 Required documents available to the public THE ORGANIZATION HAS A FORMAL POLICY FOR PUBLIC DISCLOSURE AND INSPECTION OF DOCUMENTS. THE POLICY IS POSTED ON THE ORGANIZATION'S WEBSITE. Form 990, Part IX, Line 11g Other Fees OTHER FEES - Total Expense: 11657128, Program Service Expense: 9178976, Management and General Expenses: 2147034, Fundraising Expenses: 331118;